1. Home
  2. MURA vs SCOR Comparison

MURA vs SCOR Comparison

Compare MURA & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • SCOR
  • Stock Information
  • Founded
  • MURA 2013
  • SCOR 1999
  • Country
  • MURA Ireland
  • SCOR United States
  • Employees
  • MURA N/A
  • SCOR N/A
  • Industry
  • MURA
  • SCOR Business Services
  • Sector
  • MURA
  • SCOR Consumer Discretionary
  • Exchange
  • MURA Nasdaq
  • SCOR Nasdaq
  • Market Cap
  • MURA 36.0M
  • SCOR 37.1M
  • IPO Year
  • MURA N/A
  • SCOR 2007
  • Fundamental
  • Price
  • MURA $2.10
  • SCOR $6.32
  • Analyst Decision
  • MURA Buy
  • SCOR
  • Analyst Count
  • MURA 2
  • SCOR 0
  • Target Price
  • MURA $6.00
  • SCOR N/A
  • AVG Volume (30 Days)
  • MURA 112.3K
  • SCOR 14.9K
  • Earning Date
  • MURA 11-06-2025
  • SCOR 11-04-2025
  • Dividend Yield
  • MURA N/A
  • SCOR N/A
  • EPS Growth
  • MURA N/A
  • SCOR N/A
  • EPS
  • MURA N/A
  • SCOR N/A
  • Revenue
  • MURA N/A
  • SCOR $358,940,000.00
  • Revenue This Year
  • MURA N/A
  • SCOR $3.45
  • Revenue Next Year
  • MURA N/A
  • SCOR $2.59
  • P/E Ratio
  • MURA N/A
  • SCOR N/A
  • Revenue Growth
  • MURA N/A
  • SCOR 0.77
  • 52 Week Low
  • MURA $0.95
  • SCOR $4.39
  • 52 Week High
  • MURA $4.74
  • SCOR $10.18
  • Technical
  • Relative Strength Index (RSI)
  • MURA 51.21
  • SCOR 42.49
  • Support Level
  • MURA $2.06
  • SCOR $6.42
  • Resistance Level
  • MURA $2.10
  • SCOR $6.89
  • Average True Range (ATR)
  • MURA 0.02
  • SCOR 0.49
  • MACD
  • MURA -0.00
  • SCOR -0.08
  • Stochastic Oscillator
  • MURA 50.00
  • SCOR 24.63

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About SCOR comScore Inc.

comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.

Share on Social Networks: